Table 5 Comparison of ROC–AUCs, sensitivity and specificity for ROMA, CA125 (U/ml) and HE4 (pM), discriminating malignant including borderline tumors from benign tumors
From: High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer
Premenopausal^ | n= 123 | Premenopausal^ | ||||
|---|---|---|---|---|---|---|
AUC | 95% CI | n= 123 | cutoff | sens (%) | spec (%) | |
HE4 | 0,73 | 0,58-0,87 | ROMA | 4,6% | 82 | 75 |
CA125 | 0,82 | 0,73-0,92 | CA125 | 35 | 59 | 68 |
ROMA | 0,73 | 0,58-0,88 | HE4 | 39 | 82 | 75 |
HE4 | 60 | 59 | 77 | |||
HE4 | 70 | 41 | 89 | |||
Postmenopausal^^ | n= 154 | Postmenopausal^^ | ||||
AUC | 95% CI | n= 154 | cutoff | sens (%) | spec (%) | |
HE4 | 0,91 | 0,87-0,96 | ROMA | 10,4% | 99 | 75 |
CA125 | 0,91 | 0,87-0,96 | CA125 | 35 | 82 | 84 |
ROMA | 0,94 | 0,90-0,98 | HE4 | 70 | 90 | 75 |
HE4 | 100 | 80 | 86 | |||
HE4 | 120 | 72 | 91 |